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Gluten sensitivityAbstract Despite great advances in clarifying the pathogenesis of multiple sclerosis (MS), the exact
underlying mechanism has not been deﬁnitely established. However, the responsibility of cross-
reactive antibodies as the initiating factor in MS pathogenesis is a novel idea. Recently, an antibody
against-a-gliadin 33-mer peptide which is found in most patients with gluten sensitivity have shown
to cross-react signiﬁcantly with various neural antigens including asialoganglioside, synapsin, and
myelin basic protein (MBP). Furthermore, evidence indicates that IL-17, circulating immune
complexes and even antibodies produced during gluten sensitivity can contribute to blood–brain
barrier (BBB) permeability. Accordingly, extravasation of these anti-a-gliadin antibodies
(AGA; especially IgG isotype) through the impaired BBB thought to target asialoganglioside,
synapsin, and MBP in neurons. This opsonization may trigger a series of cascade pathways
including complement activation, antibody-dependent microglial cytotoxicity against neurons,
secretion of inﬂammatory mediators, myelin sheath damage, chemokine expression, CNS
inﬂammation, BBB disruption and then leukocyte inﬁltration. The present hypothesis introducesniversity
Antibody against a-gliadin 33-mer peptide 39a new antibody-dependent alternative pathway which may lead to multiple sclerosis (MS) during
gluten sensitivity.
ª 2015 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Gluten is the most widely used food to trigger development of
multiple autoimmune diseases and neurological disorders. It
can be found in wheat (being the main source), spelt, barley,
rye, andmalts. Following intake of gluten-containing diet, intesti-
nal microbial ﬂora cleaves gluten to insoluble glutenin and sol-
uble gliadin which is divided into three main types of a, k, and
x. Antigenic properties of gluten is largely attributed to an
immunodominant 33-mer peptide (amino acid sequence
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) found in
a-gliadin. This antigenicity may be due to the fact that gluten
and gliadin used today is not the same ones used over the past dec-
ades. Really, apart from the genetic modiﬁcation, gluten has also
been undergone a remarkable hybridization and deamination
over the years. Although these procedures have been widely used
to improve the yield and tomake it easier to use, but itmay induce
biochemical and sequential changes in gluten/gliadin structure
that may result in gluten sensitivity in human [1,2].
Gluten sensitivity (also gluten intolerance) is a spectrum of
disorders including celiac disease (CD) and irritable bowel syn-
drome (IBS) in which gluten intake in genetically susceptible
individuals (carry genotypes DR4, DQ8 and/or DR3, DQ2)
cause a variety of histopathological manifestation such as
intraepithelial lymphocytosis, lamina properia inﬂammation,
and vilous atrophy. Gluten sensitivity has often been consid-
ered as a Th1 and Th17-mediated disease and IgG or IgA anti-
gliadin antibodies (AGA) are found in approximately 40–50%
of patients [3–5].
The antigenic changes of a-gliadin have also resulted in its
immunological cross-reaction with many tissue antigens
such as hepatocyte, glutamic acid decarboxylase-65, adrenal
21-hydroxylase, and myocardial peptide. Accordingly, the
relationship between gluten sensitivity and development of
autoimmune injury to the skin, joints, liver, thyroid, and
pancreas has been reported [3]. Furthermore, signiﬁcant
cross-reaction of a-gliadin-speciﬁc antibodies with nervous
system proteins such as asialoganglioside (major constituents
of neuronal cell membranes), synapsin (protein presents in
the nerve terminal of axons, speciﬁcally in the membranes of
synaptic vesicles) and myelin basic protein (one of the key
structural elements of the myelin sheath) may suggest a poten-
tial role for gliadin in the initiation of CNS autoimmunity [2].
Since destruction of myelin sheaths of neurons by auto-
immune responses is the main histopathological feature of
multiple sclerosis and its experimental model (EAE; experi-
mental autoimmune encephalomyelitis), a-gliadin seems to have
the same potential to develop demyelination of CNS by evoking
cross-reactive responses against various neural antigens.
Although many studies have reported that leukocyte
inﬁltration through an impaired BBB is the early starter of MS
disease [6,7] but in the present hypothesis ‘‘extravasation of
serum anti-a gliadin antibodies through the impaired BBB’’
has considered as an upstream event that may lead to leukocyte
inﬁltration and CNS demyelination during gluten sensitivity.Hypothesis
Fig. 1 provides an overview for the details and steps which may
lead to MS during gluten sensitivity. The list outlined below
divides the pathogenesis of anti-a gliadin antibody mediated
MS into four major steps:
1. Gluten intake in genetically susceptible people (individuals
who carry risk alleles for both CD and MS) can lead to
generation of antibodies (both IgG and IgA isotypes)
especially against a deaminated immunodominant 33-ami-
noacid peptide of a-gliadin. Previously it has been shown
that this antibody can bind to neural antigens of asialogan-
glioside, synapsin, and MBP.
2. The intact BBB is impermeable to serum anti-a-gliadin
antibodies. Nonetheless, during gluten sensitivity, IL-17
produced by TH17 subset and/or circulating small immune
complexes may contribute to BBB permeability to serum
antibodies (especially IgG isotype). Moreover, high afﬁnity
of serum anti-gliadin antibodies (AGA) for the blood–brain
barrier vasculature can promote and/or accelerate BBB
breaching. In this way, serum anti-a-gliadin antibodies
(especially IgG isotype) can gain access to the CNS
parenchyma.
3. Targeting of asialoganglioside (which is highly concen-
trated in glial and axonal structures at the nodes of
ranvier) by anti-a-gliadin antibodies may lead to activa-
tion of complement system, Fc-receptor mediated phago-
cytosis by microglial cells, and/or antibody-dependent cell
cytotoxicity (ADCC). Simultaneously, secretion of inﬂam-
matory mediators (prostaglandin E2, nitric oxide,
chemokines such as CC-chemokine ligand 2 (CCL2),
and pro-inﬂammatory cytokines such as interleukin
(IL)-1beta, IL-6, and tumor necrosis factor-alpha) by
activated microglial cells can contribute to myelin sheath
damage. Moreover, inﬂammatory responses within the
CNS induce BBB endothelial to activate and express cell
adhesion molecules.
Even though expression of MBP in inner layers of intact
myelin sheath makes it primarily inaccessible to immune sys-
tem, but emergence of MBP epitopes following myelin sheath
damage may expose it to cross-reactive antibodies. Therefore,
targeting of MBP in myelin sheath by anti-a-gliadin-antibodies
may contribute to a series of inﬂammatory responses as men-
tioned in the previous step.
1. An inevitable consequence of such CNS inﬂammation is a
broken BBB to recruit leukocytes in response to chemoki-
nes and/or danger signals released from the inﬂamed foci.
The recruited cells may include neutrophils, monocytes,
dendritic cells, B cells, and peripheral myelin- and gliadin-
reactive T cells. Afterwards, presentation of myelin epitopes
to TCD4 cells by the corresponding HLA class II alleles
and subsequent polarization into TH1 and/or TH17 subsets
Fig. 1 Schematic representation for the proposed role of anti-a-gliadin antibody in initiation of MS.
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trated leukocytes. These inﬂammatory events sustain the
BBB break down and CNS demyelination.
Evaluation of hypothesis
The present hypothesis can be tested or validated on the basis of
EAE studies. The studywill be conducted to conﬁrm the abilitiesof a-gliadin-speciﬁc antibodies to cross the BBB through vari-
ous mechanisms and trigger autoimmune demyelination.
Transgenic mice expressing risk alleles for both CD and
EAE at 6–8 weeks old will be randomly divided into two
groups. Mice will be subcutaneously immunized with complete
freund adjuvant (CFA) for control group or a-gliadin 33-mer
peptide emulsiﬁed in CFA for treatment group, respectively.
On days 0 and 2, mice will be intraperitoneally injected with
pertussis toxin. Following immunization, the diet will be
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at different time points and brain and spinal cord tissues will
be harvested. After preparation of histopathological sections,
using an antibody to mouse IgG and then HRP conjugated
secondary antibody, immunohistochemical (IHC) staining
procedure should be performed to detect presence of antibod-
ies within the CNS. Simultaneously, H&E and luxol fast blue
staining methods will be used to probe inﬁltrated mononuclear
cells and demyelinated regions [10]. Early detection of antibod-
ies will indicate that passage of antibodies through the BBB is
prior to inﬁltration of inﬂammatory cells. Moreover, detection
of demyelination in antibody localized regions along with a
delayed leukocyte inﬁltration will conﬁrm the accuracy of
the hypothesis.
Discussion
It has been shown that anti-CNS immune responses can be
initiated outside the CNS by pathogens or allergens express-
ing epitopes similar to an endogenous CNS antigen (a
molecular mimic) [11]. Accordingly, the dietary allergens
may serve as an antigenic stimulus in the etiology of MS
by emerging a cross-reactive immune response to myelin
antigen(s). In the case of EAE, it has been shown that butyr-
ophilin (BTN; a milk protein which have same epitopes with
MOG) can eighter induce or alternatively suppress encephal-
itogenic T cells to myelin oligodendrocyte glycoprotein
(MOG; a major myelin antigen for the autoimmune response
in both MS and EAE) via cross-reactivity or molecular
mimicry [12].
Similarly, in the case of gluten sensitivity, antibodies pro-
duced against an a-gliadin 33-mer peptide have been shown
to cross-react with a variety of neural antigens including
asialoganglioside, synapsin, and MBP [2]. However, an intact
BBB can effectively restrict contribution of these auto-reactive
responses to CNS autoimmunity. Accordingly, the disrupted
BBB has been mentioned as the main prerequisite for develop-
ing MS in all proposed mechanisms [13]. In the case of gluten
sensitivity which is often deﬁned as the TH1/TH17 mediated
autoimmunity, BBB permeability can be increased by IL-17
derived from activated TH17 subset. Previously, it has been
demonstrated that during EAE, IL-17 through induction of
NADPH-oxidase-dependent reactive oxygen species (ROS)
can activate the endothelial contractile machinery by occludin
down-regulation in BBB tight junctions [14].
Alternatively, circulating immune complexes found in the
majority of patients with gluten-sensitive enteropathy (GSE)
has thought to contribute to vasculitis and BBB leakage.
During gluten enteropathy, the increased permeability of the
gut to gluten and gliadin has been shown to contribute to
formation of small immune complexes through speciﬁc inter-
action with serum AGA [15,16]. Since these small immune
complexes are difﬁculty cleared by phagocytes, they may con-
centrate and deposit in vessels’ wall. Subsequently, activation
of the complement system on microvessel walls may lead to
disruption of BBB [17,18].
Also, high afﬁnity of serum anti-gliadin antibodies for the
blood–brain barrier vasculature in patients with CD has been
proposed to be involved in altering BBB permeability by
induction of structural changes [19]. Consistent with above evi-
dence, an isolated vasculitis of the CNS has been shown in one
patient with celiac disease [20].Additionally, many acute stresses (such as hypoxia,
hyperthermia, transient hypertension, and anesthesia), some
chemicals and toxins have been demonstrated to increase
BBB permeability [21].
Since the ability of serum antibodies to pass through the
disrupted BBB has been proven, numerous reports have indi-
cated a relationship between circulating antibodies and CNS
disorders.
Kuang et al. (2004) has reported that extravasation of non-
speciﬁc serum IgG through the transiently opened BBB cause
to activation of microglial and endothelial cells [22]. Moreover,
during epileptogenesis, the BBB leakage to non-speciﬁc serum
IgG has been shown to cause a remarkable eosinophilia,
shrinkage, and ultra-structural degenerative changes in
neurons [23].
Alternatively, intraperitoneal injection of IgG samples from
amyotrophic lateral sclerosis (ALS) and/or from guinea pig
with experimental autoimmune gray matter disease
(EAGMD) has been shown to initiate an inﬂammatory
reaction in the spinal cord characterized by the recruitment
of activated microglial cells [24].
Ulvested et al. (1994) has been shown that interaction of
IgG with Fc-c receptor on cultured human microglia cells
can induce respiratory burst, ADCC and phagocytosis of anti-
body-coated targets [25]. Moreover, intra-cortex injection of
auto-serum IgG in rats has been shown to cause intra
parenchymal neutrophil inﬁltration, microglial activation and
endothelial ICAM-1 expression [26]. Demyelination has also
been shown to be induced by toxic products of activated
microglial cells such as TNF-a, proteases, reactive oxygen
and nitrogen species [27,28].
Additionally, presence of antigen–antibody immune com-
plexes within the CNS has been shown to cause a series of
events including activation and recruitment of microglia cells,
complement cascade activation, long-lasting robust inﬂamma-
tory responses, BBB disruption and also leukocyte recruitment
[29–32]. Also, intra-cerebroventricular injection of the terminal
complement complex (MAC; C5b-9) in rats has been reported
to induce a CNS inﬂammation followed by leukocyte inﬁltra-
tion [33].
All of the above evidences indicate that each of IgG
extravasation, immune complex formation and/or complement
activation in CNS can result in CNS inﬂammation, BBB
disruption and then leukocyte inﬁltration. Accordingly, extra-
vasation of serum anti-gliadin antibodies through the impaired
BBB (eighter induced by IL-17 or alternatively by circulating
immune complex), seems to have the same potencies to trigger
above-mentioned events via cross-reaction with neural
antigens.
In the case of gluten sensitivity, although an association
between anti-gluten or anti-gliadin serum antibodies and
CNS autoimmune diseases such as MS has been reported
[34–37] but there are few reports regarding extravasation of
AGA through BBB and its consequences.
However, detection of anti-gliadin antibodies in the CSF of
a patient with a neurological autoimmune disorder (Ramsay
Hunt Syndrome) may support the ability of AGA to breach
the BBB [38].
Also high levels of IgG antibody against gliadin in individu-
als with gluten ataxia, schizophrenia and a subset of children
with autism may highlight contribution of humoral immune
responses to CNS pathology [39–41]. Apart from the possible
42 A. Mokarizadeh et al.role of other environmental co-factors, these differential effects
of AGA in CNS may be partly attributed to different genetic
background of patients and also genetic diversity of a-gliadin
which determine its antigenic/cross-reaction patterns.
Altogether, the role of gluten sensitivity in predisposition to
MS disease and also the possible involved mechanism(s)
remain a controversial issue and require additional research.
Even though a signiﬁcant increase in titer of anti-gliadin
antibodies has been reported in some patients with MS
[35,42,43], but the speciﬁc role of these antibodies in the patho-
genesis of MS has remained unknown. Apart from sporadic
case reports [44–46], few studies have reported an increased
prevalence of celiac disease among MS patients [35,47].
Conversely, some other studies have not found a relationship
between celiac disease and MS [48,49]. These discrepancies
may be explained by these facts that not all CD patients have
anti-a-gliadin antibodies and also, the etiology of MS is linked
to a variety of genetic and environmental factors beyond glia-
din. Furthermore, onset of MS during gluten sensitivity may
need to both genetic susceptibility and long-lasting gluten/glia-
din intake where early incidence of enteropathic disorders
necessitates patients to leave this diet.
Concerning the important role of genetic predisposition in
pathogenesis of both diseases (MS and CD), it should be noted
that even though the identiﬁed HLA risk alleles or haplotypes
for MS and CD is different (HLA-DQ2 and DQ8 haplotypes
for CD, and HLA-DR1*1501 and DR2 haplotypes for MS)
but co-expression of different allele combinations in a certain
population (individuals who carry risk alleles for both CD
and MS) is likely. Therefore, the increased prevalence of CD
among patients with MS may be largely explained within this
subpopulation. Additionally, a limited genetic overlap
(PRKCQ and IL-12 loci) has been found between MS and
CD [50].
Further reasons for responsibility of cross-reactive antibod-
ies as initiating factor in MS pathogenesis may refer to three
outlined below facts. First, according to size/molecular
weight-based permeability of the BBB to various macro-
molecules, IgG passage is prior to passage of cells even in
the case of impaired BBB [51,52]. The second fact is that even
though circulating myelin speciﬁc auto-reactive T cells are
found in both healthy individuals and MS patients [53–55],
but in patients with neurodegenerative diseases which almost
have the impaired BBB, the incidence of MS has not shown
to increase signiﬁcantly. Additionally, susceptibility of female
individuals to MS may be highly explained by their more pre-
dispositions to produce cross-reactive antibodies.
Conclusion
Collectively, the present hypothesis ﬁrst introduces a-gliadin as
one of the potent dietary allergens which may be involved in
MS pathogenesis. Furthermore, as a new concept in MS etiol-
ogy, anti a-gliadin 33-mer peptide antibodies are proposed to
play a key role in the initiation of autoimmune response in
MS during gluten sensitivity. In this paradigm, BBB break-
down, CNS inﬂammation, and subsequent leukocyte inﬁltra-
tion are the consequences of interactions between
inﬂammatory cytokines, AGA and various circulating, BBB,
and neural antigens.Overview box
First Question: What do we know already about the
subject?
The role of gluten sensitivity in predisposition to MS
disease and also the possible involved mechanism(s)
remain a controversial issue and require additional
research. Moreover, even though a signiﬁcant increase
in titers of anti-gliadin antibodies has been reported in
some patients with MS, but the speciﬁc role of these
antibodies in the pathogenesis of MS has remained
unknown.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
The present hypothesis has explained the pathways by
which anti-a-gliadin antibodies may trigger initiation of
autoimmune response in MS during gluten sensitivity.
Third Question: Among numerous available studies,
what special further study is proposed for testing the idea?
Transgenic mice (expressing risk alleles for both CD
and EAE) at 6–8 weeks old will be subcutaneously immu-
nized with complete freund adjuvant (CFA) for control
group or a-gliadin 33-mer peptide emulsiﬁed in CFA for
treatment group, respectively. On days 0 and 2, mice will
be intraperitoneally injected with pertussis toxin.
Following immunization, the diet will be switched to glu-
ten-containing food. Mice will be sacriﬁced at different
time points and brain and spinal cord tissues will be har-
vested. After preparation of histopathological sections,
IHC staining procedure should be performed to detect
presence of antibodies within the CNS. Simultaneously,
H&E and luxol fast blue staining methods will be used
to explore mononuclear cell inﬁltration and demyelina-
tion. Early detection of antibodies will indicate that cross-
ing of antibodies through the BBB is prior to
inﬂammatory cells. Moreover, detection of demyelination
in antibody localized regions along with a delayed leuko-
cyte inﬁltration will conﬁrm the accuracy of the
hypothesis.Conﬂict of interest
The authors claim no conﬂict of interest.
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